** Brokerage H.C. Wainwright starts coverage of drug developer Palvella Therapeutics PVLA.O with "buy" rating and PT of $38 - a 3x upside to Tuesday's close
** Co is testing a topical form of rapamycin called Qtorin in late-stage studies to treat two rare and chronic skin diseases called microcystic lymphatic malformations and cutaneous venous malformations
** There is a high unmet need because no approved therapies exist for these conditions - H.C. Wainwright
** Brokerage says Palvella's formulation addresses critical limitations of other forms of the drug, such as poor skin penetration, systemic toxicity, and chemical instability
** Says doctors have expressed optimism about the potential for a topical rapamycin therapy, as current treatments such as lasers, surgery or off-label medicines are either ineffective or only provide temporary relief
** Late-stage data from one of the trials is expected in early 2026 and brokerage says the drug could be launched by 2027
** Also expects sales of Qtorin rapamycin to grow to $381 million by 2034
** As of last close, stock down ~19% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。